Making newer diabetes medicines safer for people with diabetes and kidney disease
Optimizing the Safety of the Newer Diabetes Medications in Patients with Diabetes and Kidney Disease
This work looks at how SGLT2 inhibitors and GLP‑1 receptor agonists affect safety in people with diabetes and kidney disease using large real‑world health records.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11310849 on NIH RePORTER |
What this research studies
You will not be asked to take any new medications; instead, researchers will analyze de‑identified electronic health records and insurance claims from across the country to see how these newer diabetes drugs perform in people with kidney disease. They will look for side effects, hospitalizations, and harmful drug‑drug interactions in older, sicker patients who were often left out of clinical trials. The team will use large national databases to get much bigger patient numbers than trials had, allowing them to study rare but important safety problems. Their goal is to create clear information clinicians can use to prescribe these medicines more safely to people like you.
Who could benefit from this research
Good fit: Adults with type 2 diabetes and chronic kidney disease—especially older adults with multiple other health problems and taking many medicines—are the most relevant group for this work.
Not a fit: People without diabetes or kidney disease, or those whose care is not captured in large national healthcare databases, are unlikely to benefit directly from these findings.
Why it matters
Potential benefit: If successful, this could help doctors prescribe SGLT2 inhibitors and GLP‑1 receptor agonists more safely for people with diabetes and kidney disease, reducing side effects and dangerous drug interactions.
How similar studies have performed: Large randomized trials have shown cardiovascular and kidney benefits for these drug classes, but safety in frail, multimorbid patients has been less studied, so this real‑world approach addresses that gap.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Paik, Julie — Brigham and Women's Hospital
- Study coordinator: Paik, Julie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.